Half-matched stem cell transplant for graft failure rescue
Part of Blood & lymphatic clinical trials.
This trial tests a rescue stem cell transplant using a half-matched donor and a drug called cyclophosphamide to help the new stem cells grow and prevent rejection. It may help people whose first transplant failed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 3 and 70 years old.
- You can have any blood or immune disease, but your first stem cell transplant must have failed (either it didn't take or it stopped working within 60 days).
- You should have a half-matched (haploidentical) donor — such as a parent, sibling, adult child, or cousin — who is willing to donate.
- Your heart, liver, and kidneys must be working well enough to handle the treatment drugs.
- You must not have certain infections (like HIV or active hepatitis) or a recent COVID-19 vaccine or infection (within 3 months).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a second transplant using a half-matched donor for people whose first transplant failed. It may help if you have a blood cancer and are otherwise healthy enough for another procedure.
This study tests a modified second stem cell transplant for people whose first transplant failed. It uses half-matched (haploidentical) donor cells to try to restore healthy blood cells and treat the cancer.
This trial tests whether a stem cell transplant from a fully matched sibling donor can help people with serious blood disorders like sickle cell disease or thalassemia. It aims to replace the faulty blood system with a healthy one from the donor.
This trial tests a stem cell transplant from a family donor whose tissue type is only partly matched, for adults with blood cancers who don't have a fully matched sibling or other closely matched donor. The goal is to make transplant possible for more patients.
This trial tests a stem cell transplant option for children or young adults with severe aplastic anemia that did not respond to prior immune-suppressing treatment. It uses a “half-matched” donor and gives post-transplant cyclophosphamide to help the donor cells work and reduce certain immune reactions.
This trial tests a stem cell transplant from a closely matched but not fully matched family donor (haploidentical), with chemotherapy after the transplant to help prevent graft-versus-host disease (GVHD). It may help people with severe aplastic anemia, certain MDS after transformation, or PNH when other treatments have not worked or are not available.
Hear when a new Hematologic Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.